HCYP2MAG-62K
MILLIPLEX® Human Cytokine/Chemokine Magnetic Bead Panel II - Immunology Multiplex Assay
Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.
Synonyme(s) :
Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12161503
eCl@ss :
32161000
Nomenclature NACRES :
NA.84
Produits recommandés
Niveau de qualité
Espèces réactives
human
Fabricant/nom de marque
Milliplex®
assay range
accuracy: 81-110%
sensitivity: 0.4-55.8 pg/mL
standard curve range: 1.0-100,000 pg/mL
Technique(s)
multiplexing: suitable
Méthode de détection
fluorometric (Luminex xMAP)
Conditions d'expédition
wet ice
Catégories apparentées
Description générale
“Cytokine” is a general term used for a diverse group of soluble proteins and peptides which act as regulators under both normal and pathological conditions to modulate the functional activities of individual cells and tissues. These proteins also mediate direct interactions between cells and regulate processes taking place in the extracellular environment. The cytokine group of proteins includes lymphokines, interferons, colony stimulating factors and chemokines. Cytokine and chemokine research plays a significant role in achieving a deeper understanding of the immune system and its multi-faceted response to most antigens, as well as disease states such as inflammatory disease, allergic reactions, irritable bowel disease (IBD), sepsis, and cancer.
The MILLIPLEX® Human Cytokine / Chemokine Panel II enables you to focus on the therapeutic potential of cytokines as well as the modulation of cytokine expression.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Cytokines/Chemokines
The MILLIPLEX® Human Cytokine / Chemokine Panel II enables you to focus on the therapeutic potential of cytokines as well as the modulation of cytokine expression.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Cytokines/Chemokines
Spécificité
Cross Reactivty
There was no or negligible cross-reactivity between the antibodies and any of the other analytes in this panel.
There was no or negligible cross-reactivity between the antibodies and any of the other analytes in this panel.
Application
- Analytes: 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, I-309, IL-16, IL-20, IL-21, IL-23, IL-28A, IL-33, LIF, MCP-2, MCP-4, MIP-1δ, SCF, SDF-1A+β, TARC, TPO, TRAIL, TSLP
- Recommended Sample type: Serum, plasma, cell culture supernatant
- Recommended Sample dilution: neat
- Assay Run Time: Overnight or two-hour primary incubation. For best results, an overnight incubation is recommended
- Research Category: Inflammation & Immunology
- Research Subcategory: Obesity, Metabolic Disorders, Inflammation & Autoimmune Mechanisms
Caractéristiques et avantages
Design your multiplex kit by choosing available analytes within this panel.
Conditionnement
96 well plate
Stockage et stabilité
Recommended storage for kit components is 2 - 8°C.
Autres remarques
Please contact Technical Service for linearity of dilution.
Informations légales
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Mention d'avertissement
Danger
Mentions de danger
Classification des risques
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
Organes cibles
Respiratory Tract
Code de la classe de stockage
10 - Combustible liquids
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Fawaz Y Azizieh et al.
Journal of inflammation research, 12, 99-108 (2019-05-24)
Objective: In addition to some well-characterized bone turnover markers (BTMs), cytokines and adipokines have also been suggested to be linked to osteoporosis seen in menopause. However, there is much controversy on the possible association between these markers and bone mineral density
Cecilia K Andersson et al.
The Journal of allergy and clinical immunology, 139(6), 1819-1829 (2016-10-18)
Neutrophils and IL-17A have been linked mechanistically in models of allergic airways disease and have been associated with asthma severity. However, their role in pediatric asthma is unknown. We sought to investigate the role of neutrophils and the IL-17A pathway
Evidence of enhanced systemic inflammation in stable kidney transplant recipients with low Framingham risk scores.
Mansell, H; Rosaasen, N; Dean, J; Shoker, A
Clinical Transplantation null
Beatriz M Carreno et al.
The Journal of clinical investigation, 123(8), 3383-3394 (2013-07-23)
Systemic administration of IL-12p70 has demonstrated clinical activity in cancer patients, but dose-limiting toxicities have hindered its incorporation in vaccine formulations. Here, we report on the immunological and clinical outcomes upon vaccination with CD40L/IFN-γ-matured, IL-12p70-producing DCs. 7 HLA-A*0201+ newly diagnosed
Carsten U Niemann et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(7), 1572-1582 (2015-12-15)
Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental interactions for proliferation and survival that are at least partially mediated through B-cell receptor (BCR) signaling. Ibrutinib, a Bruton tyrosine kinase inhibitor, disrupts BCR signaling and leads to the egress of tumor
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique